Dr Colin Hayward, Telix Chief Medical Officer, said, “Building on the success of ZIRCON and positive
preliminary results in investigator-initiated studies of TLX250-CDx in bladder and breast cancer,
4 dosing a first patient in the STARBURST study is a strategically important milestone for Telix. This
study will add value and clinical insight to the platform and enable Telix to assess the potential of
CAIX as a biomarker as we continue to scout the theranostic potential of targeting CAIX beyond
renal cancer. We would like to thank Dr Kiser and his clinical team at Carilion Clinic, as well as the
patients who will contribute to the study.”
Another positive step for Telix.
Dr Colin Hayward, Telix Chief Medical Officer, said, “Building...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.52 |
Change
-1.330(7.06%) |
Mkt cap ! $5.862B | |||
| Open | High | Low | Value | Volume |
| $18.40 | $18.48 | $17.40 | $37.24M | 2.091M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4990 | $17.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.59 | 5897 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |